June 14, 2021
4 mins read

How India-South Africa is taking on Big Pharma at WTO

India and South Africa have the backing of a large number developing nations, in their demand for an eight-month temporary waiver of intellectual property (IP) rights on vaccines and medicines to treat Covid-19, reports SPS Pannu

The India-South Africa proposal which takes on Big Pharma in seeking a temporary patent waiver for the manufacture of vaccines and medicines to fight the Covid-19 pandemic has made some headway in those advanced countries, opposed to the move, have agreed to discuss the issue next week at the Geneva-based WTO.

World Trade Organisation (WTO) members agreed to begin discussions on June 17 to determine the format of negotiations and to produce a report outlining their progress on the vaccine supply plan by July 21-22, when the WTO’s general council convenes, Reuters cited a Geneva trade official as saying.

In India, Commerce Secretary Anup Wadhawan said that India and South Africa’s proposal has achieved tremendous mileage and tremendous progression at a very fast pace,” the news agency Press Trust of India (PTI) is reporting.

Wadhawan added that WTO member countries have agreed to commence text-based negotiations on the India-South Africa draft.

While the move has gained strength with the Joe Biden administration also coming out in favour of a temporary patent waiver for Covid-19 vaccines, European countries such as Germany, UK and France, home to big pharmaceutical giants, have been opposing the move.

However, these countries have come under increasing moral pressure to take a humanistic line to tackle the Covid-19 catastrophe confronting the world instead of backing their pharma giants in the pursuit of profit when the death toll in the deadly coronavirus pandemic has already crossed a staggering 376 million worldwide.

The issue was discussed at a recent G-7 meeting of the advanced countries and they veered around to the view that more companies worldwide should be given the technology to manufacture Covid-19 vaccines under a “special license.” While this may appear as a half-way house, considering the more far-reaching India-Africa proposal, it represents a significant step forward, a senior Indian government official told India Narrative.

ALSO READ: India must step up game in Africa

The European Union, supported by the UK, Switzerland and South Korea have now taken the stand that existing WTO rules allow countries to grant licences to manufacturers even without the patent-holder’s consent. This is expected to pave the way for wider production of vaccines. But if this is to happen on a war-footing as required much would depend on how far Big Pharma is willing to go to help and part with their technology on vaccines, experts point out.

India and South Africa have the backing of a large number developing nations, in their demand for an eight-month temporary waiver of intellectual property (IP) rights on vaccines and medicines to treat Covid-19. The fact that less than 1 per cent of the population in most developing countries is yet to be vaccinated only highlights the desperate need for big corporates to let go of patents and allow other companies round the globe to manufacture the vaccines. The WHO has also emphasised this aspect and made it clear that war against the pandemic cannot be won unless vaccines and medicines reach the poor countries as well. Developed nations have been arguing that a waiver would not boost production and could undermine future R&D on vaccines and medicines which is the standard rationale for patent waiver in normal times. However, the argument falls flat at a time when humankind is facing a devastating wave of death and suffering triggered by the coronavirus pandemic.

pharma

The India-South Africa proposal is broader and includes, apart from vaccines also diagnostics, therapeutics and medical devices used to treat Covid-19 patients in the patent waiver.

The United States has taken the stand that WTO members should focus on what actions might be needed to ramp up vaccine supply and on areas most likely to be accepted by others as soon as possible.

All decisions at the164-member WTO are taken by consensus and have to be agreed upon by all the member countries before approval which makes the task that much more difficult.

However, the India-South Africa proposal has set the ball rolling in the right direction and brought to the forefront the importance of a combined global effort to save humankind from the devastating coronavirus that has jumped species to wreak havoc on an unprecedented scale worldwide.

(This content is being carried under an arrangement with indianarrative.com)

ALSO READ: ‘India’s pharma sector sees huge growth in May’

Previous Story

Big push to innovations in India’s defence, aerospace sector

Next Story

G7 agrees to co-operate on cybercrime cases

Latest from -Top News

Pakistan’s Shadow War in Balochistan

At least 50 killed by Pakistan-backed death squads in Balochistan in April, says HRCB — toll expected to rise in May….reports Asian Lite News The Human Rights Council of Balochistan (HRCB) reported

Russia, Ukraine Resume Talks

The upcoming talks follow a significant hiatus in diplomatic engagement between the two nations, which have been locked in a brutal conflict since Russia’s invasion of Ukraine in February 2022 Russia and

UN Pays Tribute to Indian Soldiers

Thursday was observed as the 77th UN Peacekeepers Day, honouring the work of 61,353 peacekeepers, of whom 5,375 hailed from India….reports Asian Lite News Brigadier Amitabh Jha and Havildar Sanjay Singh, who

Modi’s New Warfare Playbook

Modi has upended the old playbook and India and Pakistan are entering dangerous new territory where nuclear deterrence is no longer a guarantee against conventional conflict…writes Collins Chong Yew Keat The India-Pakistan
Go toTop

Don't Miss

In G20 meet, 3 health sector priorities by India gain support

Union Health Minister Mansukh Mandaviya delivered the keynote address at

Indian Air Force Refuels Egyptian Rafale Fighters

The IAF Mig 29 UPG was also seen as part